Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers
15 8월 2022 - 9:55PM
Business Wire
Personalis’ NeXT Personal™ liquid biopsy assay
will be deployed in study collaboration
Personalis, Inc. has announced a collaboration with BC Cancer to
deploy a personalized liquid biopsy-based research use only (RUO)
assay for a study of patients with colorectal and pancreatic
cancers. The research efforts will deploy Personalis’ NeXT
Personal, which has demonstrated high sensitivity for detecting
circulating tumor DNA (ctDNA) from a patient’s blood sample, to
determine the best time to draw blood for ctDNA sampling for
molecular residual disease (MRD) detection. MRD describes a very
small number of cancer cells that remain in the body during or
after treatment.
Identification and tracking of MRD is an emerging focus in the
clinical care of patients with gastrointestinal cancers such as
colorectal and pancreatic cancer, which may improve overall
clinical management throughout a patient’s journey. Researchers are
also hoping to show that ctDNA is useful in identifying cancer
progression before the current standard of care tests and use the
data to do an economic analysis to assess cost-effectiveness for
healthcare systems.
“ctDNA surveillance may allow earlier detection of cancer
recurrence or progression, and therefore earlier intervention,
which may improve patient survival,” said Dr. Jonathan Loree,
Medical Oncologist at BC Cancer and Assistant Professor at the
University of British Columbia. “In addition, because utilizing
ctDNA for ongoing clinical management has the potential to reduce
healthcare expenditures, our partnered research with Personalis
will assess the costs of ctDNA-based surveillance compared to
MRI/CT based surveillance.”
“We believe the clinical management of cancer can substantially
improve with early determination of patient response and by
accurately informing changes to treatment regimens. Such
determinations offer the potential to avoid unnecessary toxicities,
improve cost-effectiveness, and increase survival,” said Dr.
Richard Chen, MD, Chief Medical Officer and Senior Vice President
of R&D at Personalis. “By collaborating with researchers at BC
Cancer on this multifaceted study, we hope to accelerate advances
in oncology practice via ultra-sensitive MRD detection.”
Approximately 220 patients will be recruited for this study from
across British Columbia to assess how ctDNA can improve cancer care
delivery.
About NeXT Personal
NeXT Personal is a next-generation, tumor-informed liquid biopsy
assay designed to detect and quantify MRD and recurrence in
patients previously diagnosed with cancer. The assay is designed to
deliver industry-leading MRD sensitivity down to the 1
part-per-million range, an approximately 10- to 100-fold
improvement over other available technologies. It leverages whole
genome sequencing of a patient’s tumor to identify up to 1,800
specially selected somatic variants that are subsequently used to
create a personalized liquid biopsy panel for each patient. This
may enable earlier detection across a broader variety of cancers
and stages, including typically challenging early-stage, low
mutational burden, and low-shedding cancers. NeXT Personal is also
designed to simultaneously detect and quantify clinically relevant
mutations in ctDNA that may be used in the future to help guide
therapy when cancer is detected. These include known targetable
cancer mutations, drug resistance mutations, and new variants that
can emerge and change over time, especially under therapeutic
pressure.
About Personalis
Personalis, Inc. is a leader in advanced cancer genomics,
enabling the next generation of precision cancer therapies and
diagnostics. The Personalis NeXT Platform® is designed to adapt to
the complex and evolving understanding of cancer, providing its
biopharmaceutical customers and clinicians with information on all
of the approximately 20,000 human genes, together with the immune
system, from a single sample. To enable cancer sequencing,
Personalis' Clinical Laboratory was built with a focus on clinical
accuracy, quality, big data, scale and efficiency. The laboratory
is GxP-aligned as well as Clinical Laboratory Improvement
Amendments of 1988-certified and College of American
Pathologists-accredited. For more information, visit the Personalis
website and follow Personalis on LinkedIn and Twitter.
About BC Cancer
BC Cancer, a program of the Provincial Health Services
Authority, is committed to reducing the incidence of cancer,
reducing the mortality from cancer and improving the quality of
life of those living with cancer. It provides a comprehensive
cancer control program for the people of British Columbia by
working with community partners to deliver a range of oncology
services, including prevention, early detection, diagnosis and
treatment, research, education, supportive care, rehabilitation and
palliative care. For more information, visit www.bccancer.bc.ca or
follow us on Twitter @BCCancer.
Forward-Looking Statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of U.S. securities
laws, including statements relating to attributes or advantages of
NeXT Personal or the NeXT Platform, expected benefits of the
company’s collaboration with BC Cancer, expected performance or
adoption of the NeXT Personal assay, Personalis’ business
opportunities, leadership, plans or expectations, or other future
events. Such forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from any anticipated results or expectations expressed or implied
by such statements. Factors that could materially affect actual
results can be found in Personalis’ filings with the U.S.
Securities and Exchange Commission, including Personalis’ most
recent reports on Forms 8-K, 10-K and 10-Q, the company’s
registration statement on Form S-3 filed on December 30, 2020, and
the company’s prospectus supplement filed on January 3, 2022, and
include those listed under the caption “Risk Factors.” Personalis
disclaims any obligation to update such forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220815005095/en/
Investor Relations Contact for Personalis: Caroline
Corner investors@personalis.com www.westwicke.com 415-202-5678
Media Contact for Personalis: Jennifer Temple
pr@personalis.com www.personalis.com 650-752-1300
Media Contact for BC Cancer: Andrea Visscher
andrea.visscher@phsa.ca www.bccancer.bc.ca 604-842-1177
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024